🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. STK-001 - Single Ascending Doses

    Stoke Therapeutics

    Dravet Syndrome

    phase 2 small molecule completed

    1 trial

  2. SUB01423MIG, SUB01423MIG, Colesevelam-matching placebo film-coated oral tablets (Unit Dose C)., Colesevelam-matching placebo film-coated oral tablets (Unit Dose D)., DISSENTEN 2 mg compresse

    Monte Rosa Therapeutics

    Bile acid diarrhoea

    phase 2 small molecule active

    1 trial

  3. Serlopitant High Dose

    VYNE Therapeutics

    Pruritus

    phase 2 small molecule completed

    1 trial

  4. Sevasemten Dose 1

    Edgewise Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    2 trials

  5. Single-dose regimen of high dosage investigational sIPV

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 2 mab completed

    1 trial

  6. Surzebiclimab

    BeiGene

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  7. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  8. TEV-48574 Dose Regimen A

    Teva Pharma GmbH

    Crohn Disease

    phase 2 small molecule active

    1 trial

  9. TEV-53275 Dose A

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule terminated

    1 trial

  10. TP-05 (lotilaner) Low Dose

    Tarsus Pharmaceuticals

    Lyme Disease

    phase 2 small molecule active

    1 trial

  11. The min-102 placebo is supplied as an oral suspension with similar appearance to min-102 drug product. min-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose

    Minoryx Therapeutics S.L.

    Rett Syndrome

    phase 2 small molecule active

    1 trial

  12. The placebo is the same as the ensifentrine suspension except that the active ensifentrine ingredient is omitted (i.e., it consists of phosphate buffered saline and surfactants only); it is also supplied as a single unit-dose LDPE translucent ampule overwrapped in a foil pouch, Ensifentrine inhalation suspension

    Lacuna Pharma Pty Ltd

    Non-Cystic Fibrosis Bronchiectasis

    phase 2 small molecule active

    1 trial

  13. Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial

  14. Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    2 trials

  15. UK-453,061 Dose 1

    Pfizer

    HIV-1

    phase 2 small molecule terminated

    1 trial

  16. Voclosporin High Dose

    Aurinia Pharmaceuticals

    Lupus Nephritis

    phase 2 small molecule completed

    1 trial

  17. Zasocitinib (Dose A)

    Takeda

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  18. amobarbital/Gel-One (one dose)

    United Therapeutics Europe Ltd

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  19. conventional therapy plus low dose hUC-MSCs treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 mab completed

    1 trial

  20. inhaled delta-8-THC 300mcg or 600mcg per dose

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule terminated

    1 trial

  21. linagliptin low dose

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  22. low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 2 mab active

    1 trial

  23. low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  24. low-dose lymphocyte immunotherapy

    Nanjing Zenshine Pharmaceuticals

    Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

    phase 2 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources